NCT01094964 - Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer | Biotech Hunter

Enrollment

242

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

October 31, 2013

Conditions

Bladder Cancer

Interventions

BIOLOGICAL

BCG solution

BIOLOGICAL

recombinant interferon alfa

DRUG

epirubicin hydrochloride

DRUG

mitomycin C

OTHER

laboratory biomarker analysis

PROCEDURE

hyperthermia treatment

PROCEDURE

quality-of-life assessment

Trial Locations (9)

RG24 9NA

RECRUITING

Basingstoke and North Hampshire NHS Foundation Trust, Basingstoke

B15 2TH

RECRUITING

Queen Elizabeth Hospital at University Hospital of Birmingham NHS Trust, Birmingham

LS9 7TF

RECRUITING

Leeds Cancer Centre at St. James's University Hospital, Leeds

LE1 5WW

RECRUITING

University Hospitals of Leicester NHS Trust, Leicester

SW17 0QT

RECRUITING

St. George's Hospital, London

WC1E 6AU

RECRUITING

University College of London Hospitals, London

M20 2LR

RECRUITING

South Manchester University Hospital, Manchester

TS19 8PE

RECRUITING

James Cook University Hospital, Middlesbrough

CF14 4XN

RECRUITING

University Hospital of Wales, Cardiff